Cargando…

Cystic fibrosis presentation in del. F508 and p. Tyr109Glyfs compound heterozygote CFTR state: a case report

The diagnosis of cystic fibrosis (CF) is commonly confirmed by molecular genetics with the presence of specific mutations of cystic fibrosis transmembrane conductance regulator (CFTR) gene. We report a case of cystic fibrosis (CF) in a 15-year-old female patient who is a compound heterozygote for CF...

Descripción completa

Detalles Bibliográficos
Autores principales: Turkalj, Mirjana, Matišić, Vid, Šimić, Arijana, Juginović, Alen, Erceg, Damir, Drinković, Dorian Tješić, Höppner, Wolfgang, Primorac, Dragan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Croatian Medical Schools 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563179/
https://www.ncbi.nlm.nih.gov/pubmed/31187952
http://dx.doi.org/10.3325//cmj.2019.60.246
_version_ 1783426490748108800
author Turkalj, Mirjana
Matišić, Vid
Šimić, Arijana
Juginović, Alen
Erceg, Damir
Drinković, Dorian Tješić
Höppner, Wolfgang
Primorac, Dragan
author_facet Turkalj, Mirjana
Matišić, Vid
Šimić, Arijana
Juginović, Alen
Erceg, Damir
Drinković, Dorian Tješić
Höppner, Wolfgang
Primorac, Dragan
author_sort Turkalj, Mirjana
collection PubMed
description The diagnosis of cystic fibrosis (CF) is commonly confirmed by molecular genetics with the presence of specific mutations of cystic fibrosis transmembrane conductance regulator (CFTR) gene. We report a case of cystic fibrosis (CF) in a 15-year-old female patient who is a compound heterozygote for CFTR gene, with delta F508 and Tyr109Glyfs mutations detected. This is the first detailed description of such a case in the medical literature. The primary CF presentation occurred at the age of 9 in the form of gastrointestinal symptoms including greasy, bulky, and foul-smelling stool. The patient exhibited delayed growth, with her height and weight being below the 5th centile for age according to the World Health Organization growth curves. Pancreatic enzyme supplement treatment was started immediately, alongside high-fat and high-calorie diet, resulting in patient’s recovery and development. DNA analysis of CFTR gene demonstrated the presence of del. F508 mutation and a rare combining deletion and insertion mutation p. Tyr109Glyfs. The combination of the two mutations is very rare in CF patients and is therefore valuable to document this case in order to provide information on disease progression, therapy options, and outcomes. With standard treatment and early diagnosis, the patient is currently doing well and is not restricted by the disease in her daily and sports activities.
format Online
Article
Text
id pubmed-6563179
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Croatian Medical Schools
record_format MEDLINE/PubMed
spelling pubmed-65631792019-06-20 Cystic fibrosis presentation in del. F508 and p. Tyr109Glyfs compound heterozygote CFTR state: a case report Turkalj, Mirjana Matišić, Vid Šimić, Arijana Juginović, Alen Erceg, Damir Drinković, Dorian Tješić Höppner, Wolfgang Primorac, Dragan Croat Med J 11th ISABS CONFERENCE The diagnosis of cystic fibrosis (CF) is commonly confirmed by molecular genetics with the presence of specific mutations of cystic fibrosis transmembrane conductance regulator (CFTR) gene. We report a case of cystic fibrosis (CF) in a 15-year-old female patient who is a compound heterozygote for CFTR gene, with delta F508 and Tyr109Glyfs mutations detected. This is the first detailed description of such a case in the medical literature. The primary CF presentation occurred at the age of 9 in the form of gastrointestinal symptoms including greasy, bulky, and foul-smelling stool. The patient exhibited delayed growth, with her height and weight being below the 5th centile for age according to the World Health Organization growth curves. Pancreatic enzyme supplement treatment was started immediately, alongside high-fat and high-calorie diet, resulting in patient’s recovery and development. DNA analysis of CFTR gene demonstrated the presence of del. F508 mutation and a rare combining deletion and insertion mutation p. Tyr109Glyfs. The combination of the two mutations is very rare in CF patients and is therefore valuable to document this case in order to provide information on disease progression, therapy options, and outcomes. With standard treatment and early diagnosis, the patient is currently doing well and is not restricted by the disease in her daily and sports activities. Croatian Medical Schools 2019-06 /pmc/articles/PMC6563179/ /pubmed/31187952 http://dx.doi.org/10.3325//cmj.2019.60.246 Text en Copyright © 2019 by the Croatian Medical Journal. All rights reserved. http://creativecommons.org/licenses/by/2.5/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 11th ISABS CONFERENCE
Turkalj, Mirjana
Matišić, Vid
Šimić, Arijana
Juginović, Alen
Erceg, Damir
Drinković, Dorian Tješić
Höppner, Wolfgang
Primorac, Dragan
Cystic fibrosis presentation in del. F508 and p. Tyr109Glyfs compound heterozygote CFTR state: a case report
title Cystic fibrosis presentation in del. F508 and p. Tyr109Glyfs compound heterozygote CFTR state: a case report
title_full Cystic fibrosis presentation in del. F508 and p. Tyr109Glyfs compound heterozygote CFTR state: a case report
title_fullStr Cystic fibrosis presentation in del. F508 and p. Tyr109Glyfs compound heterozygote CFTR state: a case report
title_full_unstemmed Cystic fibrosis presentation in del. F508 and p. Tyr109Glyfs compound heterozygote CFTR state: a case report
title_short Cystic fibrosis presentation in del. F508 and p. Tyr109Glyfs compound heterozygote CFTR state: a case report
title_sort cystic fibrosis presentation in del. f508 and p. tyr109glyfs compound heterozygote cftr state: a case report
topic 11th ISABS CONFERENCE
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563179/
https://www.ncbi.nlm.nih.gov/pubmed/31187952
http://dx.doi.org/10.3325//cmj.2019.60.246
work_keys_str_mv AT turkaljmirjana cysticfibrosispresentationindelf508andptyr109glyfscompoundheterozygotecftrstateacasereport
AT matisicvid cysticfibrosispresentationindelf508andptyr109glyfscompoundheterozygotecftrstateacasereport
AT simicarijana cysticfibrosispresentationindelf508andptyr109glyfscompoundheterozygotecftrstateacasereport
AT juginovicalen cysticfibrosispresentationindelf508andptyr109glyfscompoundheterozygotecftrstateacasereport
AT ercegdamir cysticfibrosispresentationindelf508andptyr109glyfscompoundheterozygotecftrstateacasereport
AT drinkovicdoriantjesic cysticfibrosispresentationindelf508andptyr109glyfscompoundheterozygotecftrstateacasereport
AT hoppnerwolfgang cysticfibrosispresentationindelf508andptyr109glyfscompoundheterozygotecftrstateacasereport
AT primoracdragan cysticfibrosispresentationindelf508andptyr109glyfscompoundheterozygotecftrstateacasereport